<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363056">
  <stage>Registered</stage>
  <submitdate>8/10/2012</submitdate>
  <approvaldate>8/10/2012</approvaldate>
  <actrnumber>ACTRN12612001076864</actrnumber>
  <trial_identification>
    <studytitle>Pilot study of smoking cessation in rheumatoid arthritis</studytitle>
    <scientifictitle>Lifestyle interventions to aid smoking cessation in rheumatoid arthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid arthritis</healthcondition>
    <healthcondition>smoking</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be contacted by arthritis educators from Arthritis New Zealand. Advice and support will be provided around 5 key areas - pain management, education, exercise, coping strategies and support. Telephone support will be given weekly for four weeks then at week 8. All interventions will be given in person or by phone. Patients may opt to take up some suggetsions given by the arthritis educators. Phone consultations will be 30-60minutes</interventions>
    <comparator>Standard of care - provision of Christchurch Hospital standard smoke stop advice</comparator>
    <control>Active</control>
    <interventioncode>Lifestyle</interventioncode>
    <interventioncode>Behaviour</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Smoking cessation will beassessed by subject self report</outcome>
      <timepoint>1, 3 and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>reduction in smoking will beassessed by subject self report</outcome>
      <timepoint>1, 3 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>participants beliefs about effectiveness of smoking cessation intervention</outcome>
      <timepoint>15 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Rheumatoid arthritis and smoker</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unwilling to give informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation was concealed using sealed opaque envelopes</concealment>
    <sequence>Randomised allocation into the two groups in a 1:1 ratio will be made using a computer generated randomisation list. This list will be compiled prior to any randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>31/10/2012</anticipatedstartdate>
    <actualstartdate>26/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>20/09/2013</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>38</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Lisa Stamp</primarysponsorname>
    <primarysponsoraddress>Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541, Wellesley Street, Auckland 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Otago</sponsorname>
      <sponsoraddress>P.O.Box 4345 Christchurch 8014</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Rheumatoid arthritis is a common chronic disease resulting in joint damage requiring joint replacement surgery, disability and increased mortality due to cardiovascular disease. Smoking has recently been shown to be a powerful environmental risk factor for onset of RA. Smoking also results in worse disease outcomes and reduces the efficacy of medications used to treat RA. These effects, together with the increase in cardiovascular deaths make smoking cessation the most important modifiable lifestyle factor in RA. Such lifestyle changes are particularly difficult for patients living with the stress of a painful chronic disease. through focus groups with Ra smokers five key barriers to smoking cessation have been identified (pain, exercise, education, coping strategies and support). An intervention programme addressing these areas has been developed and will be piloted</summary>
    <trialwebsite />
    <publication>1.	Aimer P, Treharne GJ, Stebbings S, Frampton C, Cameron V, Kirby S and Stamp LK. Efficacy of a Rheumatoid Arthritis-Specific Smoking Cessation Programme; a Pilot Randomized Controlled Trial. Arthritis Care Res 2016 (In press). 

2. Aimer P, Stamp LK, Stebbings S, Cameron V, Kirby S, Croft S,  Treharne GJ. Developing a tailored smoking cessation intervention for rheumatoid arthritis patients. Muscolskelet Care 2016;14(1):2-14</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>HEDC</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6011</ethicaddress>
      <ethicapprovaldate>1/11/2012</ethicapprovaldate>
      <hrec>12/STH/28</hrec>
      <ethicsubmitdate>9/10/2012</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014</address>
      <phone>+64-3-3644-0953</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Pip Aimer</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014</address>
      <phone>+64-3-364-0496</phone>
      <fax />
      <email>strph347@student.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014</address>
      <phone />
      <fax />
      <email />
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
P.O.Box 4345
Christchurch 8011
New Zealand</address>
      <phone>+6433640953</phone>
      <fax />
      <email>lisa.stamp@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>